Philips Respironics will continue to prioritize completing the remediation of the sleep and respiratory care devices under Respironics’ voluntary June 2021 recall.
The recall ultimately grew to include about 5. ... the increased scrutiny will help us to improve even more,” said Philips CEO Roy Jakobs. “With the agreement on a consent decree for Philips ...
At the time of the recall, both Philips and the FDA described potential health risks including respiratory tract illnesses, headaches, nausea, and toxic and carcinogenic effects. The FDA has said ...
CEO Roy Jakobs in January noted on ... Under the terms of the agreement, Philips Respironics will continue the recall. The company said that more than 99% of the sleep therapy devices have been ...
In 2021, Philips issued a recall of its breathing-aid machines following reports that an internal sound-dampening foam could degrade, spurring concerns that it could release harmful gases or ...
In 2022, the FDA took the rare step of ordering Philips to step up its outreach to customers about the recall including “clearer information about the health risks of its products.” ...